Entrada Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -4.95%
- Market cap
- $203.19M
- 39.15M shares
- Filings
- 474
Q3 2026−87.9% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−10.7% FY25 yoy
- $203.19M
- —
- 51.1×
- 1.0×
- -67.10%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $25,421,000 | reported | |
| FY 2024 | 2024-12-31 | $210,782,000 | reported | |
| FY 2023 | 2023-12-31 | $129,013,000 | reported |
Pharmaceutical preparations
Entrada Therapeutics, Inc. is the 149th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
VSTMVerastem, Inc.$30.9M209.1%677.6%$1.1BFHTXFoghorn Therapeutics Inc.$30.9M36.8%240.3%$123.5MCUECue Biopharma, Inc.$27.5M195.7%96.9%$137.0MCELUCelularity Inc$26.6M51.0%345.4%$21.8M
TRDAEntrada Therapeutics, Inc. (this company)$25.4M87.9%565.5%$203.2M
ALMSAlumis Inc.$24.1M—1,011.7%$796.5MNAMSNewAmsterdam Pharma Co N.V.$22.5M50.6%905.7%$2.4BCASIFCASI Pharmaceuticals, Inc.$20.7M27.4%232.0%$3.1MSCYXScynexis Inc$20.6M449.9%41.8%$32.9MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Entrada Therapeutics, Inc. · CIK 1689375 · Engraved from SEC EDGAR